MI
MTNB icon

Motiv8 Investments’s Matinas BioPharma MTNB Stock Holding History

Motiv8 Investments’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$0 Buy
+4
New +$5 ﹤0.01% 960

Other funds holding MTNB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Motiv8 Investments's MTNB Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Matinas BioPharma (MTNB) in Q4 2025: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #960 among its holdings.

30 funds tracked by Wall St. Rank hold MTNB as of Q4 2025.

  • Motiv8 Investments held 4 shares of Matinas BioPharma worth $0 as of Q4 2025.
  • Matinas BioPharma was a new Motiv8 Investments position in Q4 2025.
  • Matinas BioPharma made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #960 holding.
  • 30 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.